August 2025 in “The Journal of Sexual Medicine” This retrospective pharmacovigilance study identified 34 drugs, including finasteride and dutasteride, that may be associated with sexual dysfunction, with a higher risk observed in males aged 31-45.
7 citations
,
December 2017 in “Journal of the European Academy of Dermatology and Venereology” This study found that dutasteride use is associated with increased reports of sexual dysfunction, based on data from the U.S. Food and Drug Administration Adverse Event Reporting System.
8 citations
,
November 2023 in “Social Science & Medicine” This study suggests that gendered social factors, in addition to biological differences, contribute significantly to sex disparities in adverse drug event reports, with patient and event type influencing observed differences.
24 citations
,
October 2016 in “Oncotarget” This study found that finasteride was associated with more reproductive adverse effects, including sexual dysfunction in men and fetal harm in women, compared to minoxidil in reported alopecia cases.
August 2024 in “medRxiv (Cold Spring Harbor Laboratory)” This study found that finasteride use is associated with both known and new adverse events, which vary by gender and age, as well as some events not previously listed in the drug insert.
